152 related articles for article (PubMed ID: 2145933)
41. Peg-asparaginase for acute lymphoblastic leukemia.
Rytting M
Expert Opin Biol Ther; 2010 May; 10(5):833-9. PubMed ID: 20345338
[TBL] [Abstract][Full Text] [Related]
42. Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Salzer WL; Devidas M; Shuster JJ; Wang C; Chauvenet A; Asselin BL; Camitta BM; Kurtzberg J;
J Pediatr Hematol Oncol; 2007 Jun; 29(6):369-75. PubMed ID: 17551397
[TBL] [Abstract][Full Text] [Related]
43. [Clinical experiences with polyethylene glycol-bound E. coli L-asparaginase in patients with multiple recurrences of acute lymphoblastic leukemia].
Jürgens H; Schwamborn D; Körholz D; Wahn V; Göbel U
Klin Padiatr; 1988; 200(3):184-9. PubMed ID: 3210651
[TBL] [Abstract][Full Text] [Related]
44. Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma.
Vail DM; Thamm DH; Reiser H; Ray AS; Wolfgang GH; Watkins WJ; Babusis D; Henne IN; Hawkins MJ; Kurzman ID; Jeraj R; Vanderhoek M; Plaza S; Anderson C; Wessel MA; Robat C; Lawrence J; Tumas DB
Clin Cancer Res; 2009 May; 15(10):3503-10. PubMed ID: 19417014
[TBL] [Abstract][Full Text] [Related]
45. Pegaspargase: an alternative?
Holle LM
Ann Pharmacother; 1997 May; 31(5):616-24. PubMed ID: 9161659
[TBL] [Abstract][Full Text] [Related]
46. Proof-of-concept study: Evaluation of plasma and urinary electrolytes as markers of response to L-asparaginase therapy in dogs with high-grade lymphoma.
Sayag D; Chamel G; Bédard C; Beauchamp G; Couturier S; Ponce F; Rannou B
Vet Clin Pathol; 2020 Sep; 49(3):476-483. PubMed ID: 32955128
[TBL] [Abstract][Full Text] [Related]
47. Comparison of the effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin.
Valerius KD; Ogilvie GK; Fettman MJ; Walton JA; Richardson K; Powers BE; McNiel EA; Rogers QR
J Am Vet Med Assoc; 1999 Feb; 214(3):353-6. PubMed ID: 10023395
[TBL] [Abstract][Full Text] [Related]
48. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
Henriksen LT; Harila-Saari A; Ruud E; Abrahamsson J; Pruunsild K; Vaitkeviciene G; Jónsson ÓG; Schmiegelow K; Heyman M; Schrøder H; Albertsen BK;
Pediatr Blood Cancer; 2015 Mar; 62(3):427-33. PubMed ID: 25418987
[TBL] [Abstract][Full Text] [Related]
49. L-asparaginase-induced reversible posterior leukoencephalopathy syndrome in a child with acute lymphoblastic leukemia.
Rathi B; Azad RK; Vasudha N; Hissaria P; Sawlani V; Gupta RK
Pediatr Neurosurg; 2002 Oct; 37(4):203-5. PubMed ID: 12372914
[TBL] [Abstract][Full Text] [Related]
50. Effects of single-dose L-asparaginase on coagulation values in healthy dogs and dogs with lymphoma.
Rogers KS; Barton CL; Benson PA; Green RA
Am J Vet Res; 1992 Apr; 53(4):580-4. PubMed ID: 1586032
[TBL] [Abstract][Full Text] [Related]
51. L-asparaginase in the treatment of neoplastic diseases of the dog, cat and cow.
Hardy WD; Old LJ
Recent Results Cancer Res; 1970; 33():131-9. PubMed ID: 5005093
[No Abstract] [Full Text] [Related]
52. Safety profile of a single pegylated asparaginase (PEG-ASP) dose in remission induction for acute lymphoblastic leukemia (ALL).
Helbig G; Armatys A; Boral K; Kopinska AJ; Wozniczka K; Dworaczek M; Chromik K; Koclega A; Panz-Klapuch M; Wysocka M; Janikowska A
Neoplasma; 2018 Nov; 65(6):993-997. PubMed ID: 29940768
[TBL] [Abstract][Full Text] [Related]
53. Prospective evaluation of the safety of compounded bulk material L-asparaginase in dogs with lymphoma.
Thiman J; Northrup N; Saba C; Clarke D; Regan R; Hamilton T; Lindell H; Hofmeister E
J Vet Pharmacol Ther; 2016 Dec; 39(6):572-577. PubMed ID: 27086733
[TBL] [Abstract][Full Text] [Related]
54. [Advances on the role of pegaspargase in the treatment of childhood leukemia].
Liu L; Xie XT
Zhongguo Dang Dai Er Ke Za Zhi; 2014 Feb; 16(2):155-60. PubMed ID: 24568909
[TBL] [Abstract][Full Text] [Related]
55. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995).
Valerius KD; Ogilvie GK; Mallinckrodt CH; Getzy DM
J Am Vet Med Assoc; 1997 Feb; 210(4):512-6. PubMed ID: 9040837
[TBL] [Abstract][Full Text] [Related]
56. Cyclic combination chemotherapy of canine lymphosarcoma.
MacEwen EG; Brown NO; Patnaik AK; Hayes AA; Passe S
J Am Vet Med Assoc; 1981 Jun; 178(11):1178-81. PubMed ID: 6895078
[No Abstract] [Full Text] [Related]
57. Combination chemotherapy with continuous L-asparaginase, lomustine, and prednisone for relapsed canine lymphoma.
Saba CF; Hafeman SD; Vail DM; Thamm DH
J Vet Intern Med; 2009; 23(5):1058-63. PubMed ID: 19678892
[TBL] [Abstract][Full Text] [Related]
58. Reversible MRI lesions due to pegaspargase treatment of non-Hodgkin's lymphoma.
Bushara KO; Rust RS
Pediatr Neurol; 1997 Sep; 17(2):185-7. PubMed ID: 9367305
[TBL] [Abstract][Full Text] [Related]
59. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia.
Aguayo A; Cortes J; Thomas D; Pierce S; Keating M; Kantarjian H
Cancer; 1999 Oct; 86(7):1203-9. PubMed ID: 10506705
[TBL] [Abstract][Full Text] [Related]
60. Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia.
Yoshimoto T; Nishimura H; Saito Y; Sakurai K; Kamisaki Y; Wada H; Sako M; Tsujino G; Inada Y
Jpn J Cancer Res; 1986 Dec; 77(12):1264-70. PubMed ID: 3102431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
